Agendia To Present Multiple Predictive And Prognostic Studies On Breast And Colorectal Cancers At ASCO Annual Meeting

Main Category: Breast Cancer
Also Included In: Colorectal Cancer;  Cancer / Oncology
Article Date: 27 May 2009 - 5:00 PDT

email to a friend   printer friendly   opinions  

Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia, the University of California San Francisco and the Netherlands Cancer Institute will present data from multiple studies at the American Society of Clinical Oncology Annual Meeting, May 29 - June 2, 2009, in Orlando, Florida.

The study results further underpin the broad predictive and prognostic power of Agendia's breast cancer recurrence test MammaPrint(R) and highlight promising data on Agendia's new colon cancer recurrence test, ColoPrint(TM). Visitors can meet the Agendia team in booth #2014 and study results will be discussed at the following sessions:

Date: Saturday, May 30, 2009
ORAL PRESENTATION
Abstract #512
Time: 5:00PM - 5:15PM
Location: Level 2, West Hall D1
The 70-gene profile and chemotherapy benefit in 1,600 breast cancer patients
R. A. Bender, M. Knauer, E. J. Rutgers, A. M. Glas, F. A. de Snoo, S. C.
Linn, L. J. Van 't Veer

Date: Saturday, May 30, 2009
ORAL PRESENTATION
Abstract # LBA515
Time: 3:00PM - 6:00PM
Location: Level 2, West Hall D1
Breast cancer molecular profiles predict tumor response of neoadjuvant
Doxorubicin and Taxol, the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657)
L. J. Esserman, C. Perou, M. Cheang, A. DeMichele, L. Carey, L. J. van 't
Veer, J. Gray, E. Petricoin, K. Conway, D. Berry, I-Spy Investigators

Date: Saturday, May 30, 2009
POSTER PRESENTATION
Abstract #6570
Time: 2:00PM - 6:00PM
Location: Level 2, West Hall C
Cost effectiveness of targeting chemotherapy with the 70-gene
prognostic signature in early stage breast cancer (ESBC) patients
K. B. Tong, E. Chen, G. Brink, R. Bender, F. de Snoo, J. Malin

Date: Sunday, May 31, 2009
POSTER DISCUSSION
Abstract #535
Time: 8:00AM - 12:00PM
Location: Level 2, West Hall D1, W240A
Outcome prediction by the 70-gene profile in the context of the National
Comprehensive Cancer Network (NCCN) guideline
F. A. de Snoo, M. Knauer, R. A. Bender, L. Stork-Sloots, E. J. Rutgers,
A. M. Glas, S. C. Linn, L. J. Van 't Veer

Date: Sunday, May 31, 2009
POSTER PRESENTATION
Abstract #4036
Time: 8:00 AM - 12:00 PM
Location: Level 2, West Hall C
Development and validation of a robust prognostic and predictive
signature for colorectal cancer (CRC) patients
A. M. Glas, P. Roepman, R. Salazar, G. Capella, V. Moreno, J. Westerga,
P. J. Kuppen, I. Simon, L. J. Van 't Veer, R. Tollenaar

Date: Sunday, May 31, 2009
POSTER DISCUSSION
Abstract #518
Time: 8:00AM - 12:00PM
Location: Level 2, West Hall D1, W240A
Early determination of metastatic potential in breast cancer: the 70-gene
signature in small tumors
M. Knauer, S. Mook, V. Retèl, M. Kok, J. Wesseling, A. M. Glas, E. J.
Rutgers, L. J. van 't Veer, S. C. Linn

Date: Monday, June 01, 2009
POSTER PRESENTATION
Abstract #11083
Time: 1:00PM - 5:00PM
Location: Level 2, West Hall C
Combining multi-gene profiling of molecular subtypes with the 70-gene
profile for classification of breast cancer
L. Stork-Sloots, O. Krijgsman, P. Roepman, F. A. de Snoo, R. A. Bender, A. M. Glas

About MammaPrint(R)

MammaPrint is the first 'in vitro diagnostic multivariate index assay' (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis-patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

Source
Agendia B.V.

• Additional
• References
• Citations